Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History III1 Apr 2015MP14-15 METABOLIC SYNDROME AND AGGRESSIVE PROSTATE CANCER AND BIOCHEMICAL RECURRENCE AFTER DEFINITIVE TREATMENT Jennifer Beebe-Dimmer, Lance Heilbrun, Cathryn Bock, Daryn Smith, Izabela Podgorski, Sue Bolton, Isaac Powell, and Jennifer Beebe-Dimmer Jennifer Beebe-DimmerJennifer Beebe-Dimmer More articles by this author , Lance HeilbrunLance Heilbrun More articles by this author , Cathryn BockCathryn Bock More articles by this author , Daryn SmithDaryn Smith More articles by this author , Izabela PodgorskiIzabela Podgorski More articles by this author , Sue BoltonSue Bolton More articles by this author , Isaac PowellIsaac Powell More articles by this author , and Jennifer Beebe-DimmerJennifer Beebe-Dimmer More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.877AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Introduction: There has been some controversy about the impact of Metabolic Syndrome (MS) on prostate cancer (PC). Contributing to this controversy could be the impact of race, specifically differences in the MS profile between African American (AA) and European American (EA) men. The goal of this study was to examine the association between specific features of Metabolic Syndrome and clinical features consistent with aggressive PC in a cohort of AA and EA patients as well as biochemical recurrence (BCR) after definitive treatment. METHODS Methods: 540 men (350 AA and 190 EA) with PC diagnosed on or after January 1, 2004 were recruited into the study. Participation required completion of a questionnaire, measurement of height, weight, waist and hip circumference. MS was defined as having any 3 of 4 measured features [a history of hypertension, diabetes or hypercholesterolemia self-reported on questionnaire, or obesity (defined as having a body mass index (BMI) ¡Ý 30 kg/m2 based upon measured height and weight)]. Unconditional logistic regression was used to investigate the odds ratio (OR) for both advanced stage (¡Ý T3a, or any T, M1 or N1), and high Gleason grade (¡Ý 4+3) with MS and its individual features. Cox proportional hazards regression was used to estimate the hazard ratio (HR) for BCR associated with these same MS features. RESULTS Results: Thirty-three percent of patients were classified as having MS (36% AA vs. 27% EA). Hypertension and diabetes were more commonly reported among AA patients while hypercholesterolemia was reported more often among EA patients. Approximately 43% of all men were considered obese. Hypertension was positively associated with high-grade disease among EA (OR=2.2; 95% CI=1.1-4.4), but not among AA patients (OR=0.9; 95% CI=0.5-1.7). Hypercholesterolemia was positively associated with advanced stage among EA (OR=2.0; 95% CI=1.0-4.0), but negatively associated among AA (OR=0.4; 95% CI=0.3-0.7). There was some suggestion that hypertension was associated with an increased risk for BCR among EA (HR=2.5; 95% CI=0.7 - 9.1), but not among AA (HR=0.9; 95% CI=0.3 - 2.1). CONCLUSIONS Conclusions: Our findings suggest distinct racial differences in the association between specific features of MS with aggressive prostate cancer clinical characteristics and BCR. Further study is clearly warranted to both replicate these findings in an independent sample and determine the underlying cause of the observed differences. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e156 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jennifer Beebe-Dimmer More articles by this author Lance Heilbrun More articles by this author Cathryn Bock More articles by this author Daryn Smith More articles by this author Izabela Podgorski More articles by this author Sue Bolton More articles by this author Isaac Powell More articles by this author Jennifer Beebe-Dimmer More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call